| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.03 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.03 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.03 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.078 | 0.03 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.04 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.04 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.04 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.04 |